5 Analysts Have This to Say About Zimmer Biomet Holdings
Within the last quarter, Zimmer Biomet Holdings (NYSE:ZBH) has observed the following analyst ratings:
FDA Denies Approval For NeuroOne Medical’s Evo sEEG Electrode For Extended Use
The FDA has reviewed NeuroOne Medical Technologies Corporation’s (NASDAQ:NMTC) appeal for 510(k) clearance for its Evo sEEG Electrode for less than…
Citigroup Maintains Neutral on Zimmer Biomet Holdings, Lowers Price Target to $125
Citigroup analyst Joanne Wuensch maintains Zimmer Biomet Holdings (NYSE:ZBH) with a Neutral and lowers the price target from $135 to $125.
SVB Leerink Maintains Outperform on Zimmer Biomet Holdings, Raises Price Target to $140
SVB Leerink analyst Danielle Antalffy maintains Zimmer Biomet Holdings (NYSE:ZBH) with a Outperform and raises the price target from $135 to $140.
Zimmer Biomet Raises, Tightens FY22 Outlook after Q1 Earnings Surpass Estimates
Zimmer Biomet Holdings Inc’s (NYSE:ZBH) Q1 sales increased by 3.9% Y/Y to $1.66 billion (up 6.8% on a constant currency basis),…
Earnings Scheduled For May 3, 2022
Companies Reporting Before The Bell
• Kiniksa Pharmaceuticals (NASDAQ:KNSA) is projected to report earnings for its first quarter.
Analyst Ratings For Zimmer Biomet Holdings
Analysts have provided the following ratings for Zimmer Biomet Holdings (NYSE:ZBH) within the last quarter:
Goldman Sachs Maintains Buy on Zimmer Biomet Holdings, Lowers Price Target to $155
Goldman Sachs maintains Zimmer Biomet Holdings (NYSE:ZBH) with a Buy and lowers the price target from $179 to $155.